Candriam S.C.A. Purchases 192,702 Shares of Enliven Therapeutics, Inc. $ELVN

Candriam S.C.A. boosted its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 46.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 609,352 shares of the company’s stock after buying an additional 192,702 shares during the period. Candriam S.C.A.’s holdings in Enliven Therapeutics were worth $12,473,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. TCG Crossover Management LLC bought a new position in shares of Enliven Therapeutics during the 2nd quarter worth $9,990,000. Duquesne Family Office LLC bought a new stake in shares of Enliven Therapeutics in the second quarter valued at about $9,288,000. Franklin Resources Inc. lifted its stake in Enliven Therapeutics by 2,029.3% in the second quarter. Franklin Resources Inc. now owns 430,240 shares of the company’s stock worth $8,631,000 after acquiring an additional 410,034 shares during the period. Affinity Asset Advisors LLC bought a new position in Enliven Therapeutics during the 2nd quarter worth about $8,024,000. Finally, Marshall Wace LLP grew its holdings in Enliven Therapeutics by 2,886.9% during the 2nd quarter. Marshall Wace LLP now owns 333,333 shares of the company’s stock worth $6,687,000 after acquiring an additional 322,173 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $27.93 on Wednesday. The stock’s 50-day moving average is $21.78 and its 200 day moving average is $20.77. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.22. The company has a market cap of $1.66 billion, a P/E ratio of -15.18 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. On average, analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $41.00.

Insider Activity

In related news, CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $21.82, for a total transaction of $272,750.00. Following the completion of the transaction, the chief executive officer owned 890,392 shares in the company, valued at $19,428,353.44. The trade was a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Anish Patel sold 48,300 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the sale, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at $6,018,157.89. The trade was a 18.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 257,613 shares of company stock worth $6,665,162 in the last quarter. 25.90% of the stock is currently owned by corporate insiders.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.